EA
EDIT icon

Emerald Acquisition’s Editas Medicine EDIT Stock Holding History

Emerald Acquisition’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$253K Buy
+18,769
New +$385K ﹤0.01% 2642

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Acquisition's EDIT Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Editas Medicine (EDIT) in Q3 2016: 18,769 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #2642 among its holdings.

75 funds tracked by Wall St. Rank hold EDIT as of Q3 2016.

  • Emerald Acquisition held 18,769 shares of Editas Medicine worth $253K as of Q3 2016.
  • Editas Medicine was a new Emerald Acquisition position in Q3 2016.
  • Editas Medicine made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2642 holding.
  • 75 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.